1200 BRICKELL AVENUE, MIAMI, FL
Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain
Reports Successful Formulation Results for SKNY-1, its Oral Drug Candidate for Obesity and Addiction
Reg. FD
Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy
Appointment of Andriy Mushak as Fractional CFO; Alan Weichselbaum Departs
Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1
Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN
Mira Pharmaceuticals Announces Positive Phase 1 Results for Ketamir-2
Q3
Q2
Q1
Amended Annual Report
FY 2024
Q2 amended
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
S-1
Definitive Merger Proxy Statement
Additional Proxy Materials
PRER14A
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
PREM14A
Correspondence
Submission Upload
Prospectus Filed Pursuant to Rule 424(b)(1)